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Precis: Surgical complications are associated with little or no long-term impairment in 
quality of life in breast cancer patients undergoing mastectomy without reconstruction, or 
delayed reconstruction. The association is much larger for flap-related complications 
suffered during immediate reconstruction. 
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Background: Medical treatment for breast cancer is associated with substantial toxicity and 
patient burden. There is less known about the impact of surgical complications. 
Understanding this impact would provide important information for patients when 
considering surgical options. 
Methods: Between 2008 and 2009, the UK National Mastectomy and Breast Reconstruction 
Audit recorded surgical complications for a prospective cohort of 17,844 women treated for 
breast cancer at 270 hospitals. 6,405 of these women were surveyed about their quality of 
life 18 months after surgery. Breast appearance, emotional well-being and physical well-
being were quantified on 0-100 point scales. Linear multiple regression models were used to 
compare the scores of patients who had complications to those who did not, while 
controlling for a range of baseline prognostic factors. 
Results: The overall complication rate was 10.2%. Complications were associated with little 
or no impairment in women undergoing mastectomy without reconstruction, or delayed 
reconstruction. The association was much larger for flap-related complications suffered 
during immediate reconstruction. The breast appearance (adjusted mean difference = -23.8; 
95% CI, -31.0 to -16.6) and emotional well-being (adjusted mean difference = -14.0; 95% CI, -
22.0 to -6.0) scores of these patients were much lower than any other patient group. 
Implant-related complications were not associated with lower quality of life in any surgical 
group. 
Conclusions: There is a strong case for prospectively collecting flap complication rates at the 
surgeon and surgical unit level, and allowing patients to access this data when they make 
choices about their breast cancer surgery. 
Key words: Breast cancer; mastectomy; breast reconstruction; postoperative complications; 
quality of life.  
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Introduction 
After surgery most patients experience some degree of morbidity which can vary from 
minor discomfort and sleep disturbance to life threatening haemorrhage or infection. 
Unexpected morbidity is often referred to as a ‘complication’ and has been defined as “an 
event or occurrence that is associated with a disease or a healthcare intervention, is a 
departure from the desired course of events, and may cause, or be associated with, 
suboptimal outcome”.1 
 
The association between surgical complications and quality of life was the subject of a 2016 
systematic review. It found that in two-thirds of the 50 published studies reviewed, patients 
who suffered surgical complications had significantly worse quality of life and other 
psychosocial outcomes than those who had no complications and that this effect persisted 
in the long-term.2 
 
Intuitively, one would expect surgical morbidity to affect the quality of life of patients 
undergoing breast cancer surgery despite attempts to reduce its impact. For example, on 
average, patients who suffer skin or flap necrosis following breast reconstruction should be 
at a higher risk of having an impaired aesthetic outcome, with associated harm to emotional 
well-being, even after corrective measures such as debridement or revision surgery have 
been performed. Information on the extent of this impairment would move our 
understanding of breast surgery complications beyond simple prevalence data and help 
patients and clinicians to weigh the harms and benefits of different surgical options.  
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To our knowledge there are only two previous studies of the impact of complications on 
patients undergoing breast cancer surgery. The first compared 233 breast reconstruction 
patients who suffered a complication to 483 patients who did not. This study, which was 
retrospective and assessed patients at varying time points after their surgery, found that 
aesthetic satisfaction was significantly lower in patients who had a complication.3 The 
second compared 36 patients who suffered a complication after breast reconstruction to 
136 patients with no complications and found no difference in clinician-rated aesthetic 
outcomes.4 Both were single-centre studies that excluded patients undergoing mastectomy 
without reconstruction, and did not attempt to analyse the impact of different complication 
types. The paucity of literature may be because of methodological obstacles. The highest 
standard of evidence requires a large multi-centre study to identify a sufficient number of 
patients suffering different types of complications. It would also require the use of 
standardized definitions of complications across all centres, information about important 
clinical covariates, and the prospective collection of perioperative morbidity and patient-
reported outcomes at standardized time points. All of the above are available from the UK 
National Mastectomy and Breast Reconstruction Audit. In this paper, we use data from the 
Audit to compare the quality of life of patients who had complications after breast cancer 
surgery to those who had no complications.  
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Methods 
Patients were recruited between 1 January 2008 and 31 March 2009 at all 150 English NHS 
acute hospital trusts providing acute breast cancer treatment, six NHS acute hospitals in 
Wales and Scotland, and 114 independent hospitals in England.  Staff at these treatment 
centres prospectively recorded clinical data on women aged 16 years and over with a 
diagnosis of invasive carcinoma of the breast or ductal carcinoma in-situ undergoing 
unilateral mastectomy with or without immediate reconstruction, or primary delayed 
reconstruction following a previous mastectomy. Local staff were also asked to obtain 
written consent from eligible women to allow them to be sent follow up questionnaires. 
 
Because there is great variability in how different clinicians define complications we focused 
on post-surgical problems that required treatment. Clinicians recorded all surgical 
complications requiring some form of treatment during the hospital admission. In this 
paper, we describe three sets of perioperative complication that might be expected to have 
an impact on aesthetic outcome at the breast surgery site, with consequent impairment to 
other aspects of quality of life. First, mastectomy-site complications occurring during a 
mastectomy, mastectomy with immediate reconstruction, or delayed breast reconstruction. 
These comprised wound infection requiring intravenous antibiotics or surgical debridement, 
wound dehiscence requiring re-closure, skin flap necrosis requiring surgical debridement, 
and haematoma or seroma at the mastectomy site requiring aspiration or drainage. Second, 
flap-related complications occurring during breast reconstruction. These comprised 
impaired flap perfusion requiring re-exploration or revision of anastomosis, partial flap 
necrosis or failure requiring debridement, and total flap necrosis or failure requiring 
removal. Third, implant/expander-related complications occurring during breast 
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reconstruction. These comprised displaced implant/expander requiring re-positioning, 
infected implant/expander requiring intravenous antibiotic therapy, infected 
implant/expander requiring removal, and ruptured implant/expander requiring removal. A 
range of other clinical data items were recorded to account for confounding when patient 
groups were compared.  These included details of surgical procedures, clinical risk factors 
and sociodemographic characteristics.  
 
To collect data on long-term quality of life outcomes, questionnaires were sent to 
consenting patients at their home address 18 months after surgery. The questionnaires 
were sent by a co-ordinating team of researchers that did not include the treating hospitals 
or clinicians, once the team had confirmed the patient was still alive by cross-checking their 
details against mortality data held by the National Strategic Tracing Service.  A prepaid 
envelope was enclosed to facilitate the return of the completed questionnaire.  
Questionnaires were marked only with a unique numeric patient identifier.  Non-
respondents were sent a single reminder letter and an additional copy of the questionnaire 
at a five week interval. Each patient’s questionnaire data was linked to their associated 
clinical data using their unique numeric identifier.  The questionnaire addressed patient 
satisfaction with their breast area appearance (4 items for mastectomy-alone patients, 16 
items for reconstruction patients), emotional well-being (10 items) and physical well-being 
(16 items). The emotional well-being scale addressed issues such as confidence in a social 
setting, emotional health and self-esteem. The physical well-being scale addressed issues 
such as back and shoulder pain, breast pain and difficulty sleeping. A separate scale on 
sexual well-being was included on an optional basis. As nearly half of the follow-up sample 
(46%) declined to complete this section the results are not reported. The scales were 
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derived from the Breast-Q family of outcome measures5,6 and were pre-tested with English 
breast cancer patients by the authors prior to their use to ensure that there were no issues 
with language, comprehension or acceptability. Each scale ranges from 0 to 100 with higher 
scores representing a better outcome. We defined the minimum important difference as 0.5 
of a standard deviation, equivalent to 10 points for each scale.7 Copies of the questionnaires 
and clinical proformas are available at https://www.rcseng.ac.uk/standards-and-
research/research/clinical-effectiveness-unit/documents-and-publications/ 
 
Linear multiple regression models were used to compare the Breast-Q scale scores of 
patients who had complications to those who did not. Separate analyses were conducted 
for women who underwent mastectomy-alone, mastectomy with immediate 
reconstruction, and delayed reconstruction. The analyses were also separated for each of 
the three complication sets described above. Complications within each set were combined 
so that the set as a whole could be coded as either present or not present at the individual 
patient level. The denominator of patients varied depending on whether or not a particular 
complication was relevant to the surgical group being analysed. For example, patients who 
did not have an implant were excluded from analyses that examined the impact of implant-
related complications. The regression models included a range of baseline variables likely to 
be associated with quality of life so that the independent impact of suffering a complication 
could be estimated. The models were constructed using a backward stepwise process with 
variables dropped from the models if the strength of their association with an outcome was 
weak (p>0.05). The initial variables in each model were the patient’s age, socioeconomic 
deprivation8, ethnicity (white or other ethnic group), smoking status, Body Mass Index 
(BMI), diabetes status, American Society of Anaesthesiologists (ASA) physical status 
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classification9, Eastern Cooperative Oncology Group (ECOG) score10, tumour type (invasive 
or ductal carcinoma in situ), ductal carcinoma in situ grade (low, intermediate or high) and 
invasive carcinoma grade (well, moderately, or poorly differentiated). 
 
All statistical tests were two-sided and p-values less than 0.05 were considered to represent 
a statistically significant result.  All statistical analyses were undertaken using STATA/MP 14. 
 
At the time of the study national cancer audits were exempt from obtaining research ethics 
approval. Approval to prospectively collect patient identifiable data for analysis and 
reporting was obtained from the Patient Information Advisory Group under Section 60 of 
the Health and Social Care Act 2001. Informed written consent was obtained from women 
before they were sent follow-up questionnaires. 
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Results 
18,216 eligible women were registered within the inclusion period of whom 17,844 had a 
complete record of any complications suffered in the perioperative period. The extent to 
which patients were successfully recruited to the patient-reported outcomes component of 
the study varied across treatment centres. Of the 18,216 patients registered in the study, 
10,632 women (58%) were asked to consent to receive follow-up questionnaires. In some 
cases, hospital staff did not ask for consent due to legitimate concerns regarding poor 
eyesight (n=27), literacy or language comprehension issues (n=166), or cognitive impairment 
(n=202). However, a large number of women were not approached for this element of the 
study due to logistical problems with consent procedures. Among those women that were 
asked, 8,725 (82%) agreed to participate. After further excluding those women who died in 
the follow up period, 8,536 women (98%) had an 18 month questionnaire sent to their 
home address. 7,110 (83%) of these returned a completed 18 month questionnaire, of 
whom 6,405 successfully completed the breast appearance scale and had a complete record 
of their perioperative complications. 
 
The characteristics of the 17,844 women with complete complications data and the sub-
sample of 6,405 women with self-reported data about their breast appearance 18 months 
after surgery are shown in Table 1. The samples are very similar indicating that the sub-
sample is likely to be representative of the larger cohort. The sub-sample was younger, 
healthier and less deprived than the cohort as a whole but the differences were small. The 
proportion of women undergoing breast reconstruction surgery was higher in the sub-
sample (35%) than in the larger cohort (28%). Reassuringly, the proportion of women who 
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suffered a perioperative complication in the sub-sample (9.8%) was almost identical to that 
recorded for the larger cohort (10.2%). 
 
The proportion of women suffering different types of complications is shown in Table 2 for 
the sub-sample of women with complete follow-up data. The overall complication rate was 
10.1% for women undergoing mastectomy with no reconstruction, 10.0% for women 
undergoing mastectomy with an immediate reconstruction, and 7.6% for women 
undergoing a delayed reconstruction. The most commonly recorded complication was a 
haematoma or seroma requiring aspiration or drainage. 9.0% of women undergoing 
mastectomy-only suffered this complication compared to 4.5% of women undergoing 
immediate reconstruction and 2.3% of women undergoing delayed reconstruction. Flap-
related complications were rare but slightly more frequent in women undergoing delayed 
(5.4%) versus immediate reconstruction (3.0%). Implant-related complications were 
infrequent in both groups and were recorded for 3.3% of immediate reconstruction patients 
and 1.4% of delayed reconstruction patients. 
 
Unadjusted and adjusted differences in 18-month breast appearance scores between 
patients with and without complications are shown in Table 3. The effect of adjusting for 
baseline factors was minimal. A negative difference implies a worst breast appearance 
outcome for patients who suffered complications. In the mastectomy-only group, patient-
reported breast appearance was significantly worse for patients who had suffered a 
mastectomy site complication (adjusted mean difference = -2.7; 95% CI = -4.7 to -0.7) but 
this difference was less than the pre-defined minimally important difference of 10 points. A 
similar result was observed in the immediate reconstruction group (adjusted mean 
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difference = -7.5; 95% CI = -11.5 to -3.4) but there was no significant difference among 
delayed reconstruction patients. Patients suffering a flap-related complication had 
significantly worse breast appearance scores in the immediate reconstruction group 
(adjusted mean difference = -23.8; 95% CI = -31.0 to -16.6) and this difference was much 
larger than the minimally important difference threshold. This finding was present when the 
analysis was separated for pedicled flap procedures (p < 0.001) and free flap procedures (p < 
0.001).  Flap-related complications were not associated with significantly lower breast 
appearance scores in the delayed reconstruction group. In both the immediate and delayed 
reconstruction groups, implant-related complications were not associated with significantly 
worse breast appearance scores. 
 
A similar pattern was seen for the emotional and physical well-being scales (Tables 4 and 5). 
Mastectomy site complications were associated with small but statistically significant 
differences in favour of patients who had not had complications, but this effect was not 
seen with delayed reconstruction patients. In the immediate reconstruction group, flap 
related complications were associated with large differences in favour of those who did not 
have complications. This effect was not seen in the delayed reconstruction group. In both 
reconstruction groups implant related complications had no association with emotional and 
physical well-being. 
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Discussion 
Surgical complications were associated with little or no impairment to the quality of life of 
women undergoing mastectomy without reconstruction, or delayed reconstruction. The 
association was much larger in women who suffered flap-related complications in the 
immediate reconstruction context. The breast appearance and emotional well-being scores 
of these patients were much lower than any other patient group, including women who had 
a mastectomy with no reconstruction. Implant-related complications were not associated 
with a lower quality of life in any surgical group. Physical well-being scores showed less of 
an association with complications across all groups. 
 
The findings should be reassuring to women undergoing mastectomy with or without breast 
reconstruction. In contrast to the toxicities associated with medical treatments for breast 
cancer, which are reported as severe by 45% of patients and are associated with substantial 
impairment to quality of life, surgical complications are less frequent and associated with 
much less harm.11 The one area of concern relates to flap-related complications in women 
undergoing immediate reconstruction. This finding requires careful interpretation. The 
impact of complications on quality of life is a function of the outcome for both the women 
who suffer complications and those who do not. Flap-based reconstructions have, at the 
overall group level, a superior outcome to implant-only procedures12,13 and therefore the 
impact of flap-related complications is exacerbated because of the additional benefit that is 
lost when the operation fails. The role of patient expectations must also be considered. 
Flap-based reconstructions are more difficult to perform than implant-only procedures. 
They take longer to perform, and the recovery period is also longer. Women who choose 
this option may be trading the short-term harm hardship associated with recovering from 
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the procedure for a better long-term outcome.  Reconstructive complications and 
subsequent failure usually results in an unanticipated mastectomy for a woman expecting 
the outcomes of a flap-based immediate reconstruction. This may lead to profound 
disappointment in the small number of women affected. 
 
There was no association between flap-related complications and quality of life in the 
delayed setting.  This could be for two distinct reasons.  First, the initial reference point for 
delayed reconstruction patients is post-mastectomy, lowering expectations.  Second, unlike 
women in the immediate reconstruction group, delayed reconstruction patients do not 
require adjuvant therapies, which may exacerbate the impact of a surgical complication, and 
are more likely to have undergone corrective secondary reconstruction after initial 
reconstructive complications or failure. 
 
This study is the largest to date and has many strengths over the existing literature. 
Standardized definitions of complications were used and complication data was collected 
prospectively to reduce the risk of measurement error. Complete complication data was 
collected for 98% of eligible patients. Data on complications and quality of life were from 
different sources which reduces the risk that any observed associations were due to 
common method variance. The data was collected at 270 hospitals which increases the 
generalizability of the finds and reduces the risk that the results represent the unique 
practices of individual hospitals or surgeons. Follow-up was at 18 months which means the 
full impact of complications and any subsequent revision procedures and treatments is 
assessed. Our analysis provides separate answers for different surgical groups, including 
women who underwent mastectomy alone, a group that is often neglected by research in 
15 
 
this area. We also provide a detailed analysis of the impact of different complication types 
for the first time.  
 
The main limitation is the attrition between baseline and follow up. The follow-up cohort 
was slightly younger, healthier and less deprived than the cohort as a whole. However, the 
most important baseline prognostic factor, complication rate, was almost identical in the 
two groups. Although we adjusted for a wide range of prognostic factors, and the adjusted 
and unadjusted differences between groups were very similar, it is still possible that the 
differences we observed are due to residual confounding. The analysis of implant 
procedures in the delayed reconstruction context involves only four patients who suffered a 
complication. This means that we may have missed a real effect due to an underpowered 
statistical test. Finally, our study is limited to perioperative morbidity and does not assess 
the impact of complications occurring after discharge. 
 
Our findings are consistent with the previous literature but provide a more detailed analysis 
of specific complications and surgical groups. The results complement previous studies on 
the effectiveness of different breast reconstruction techniques: we are now able to 
characterise both the benefits and harms of these procedures. The main implication of our 
findings is that clinicians should discuss the risks associated with reconstruction procedures 
that use flaps to reconstruct the breast mound. Patients and clinicians should be aware that 
although flap procedures are, at the group level, associated with superior aesthetic 
outcomes, they carry a substantial risk for the small group of patients who suffer a flap-
related complication in the immediate reconstruction context.10,11 This risk goes beyond 
self-perceived aesthetic outcome: it also extends to emotional and physical well-being. 
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Given these consequences there is a strong case for prospectively collecting flap 
complication rates at the surgeon and surgical unit level, and allowing patients to access this 
data when they make choices about their breast cancer surgery. We have previously shown 
that this can be achieved in the United Kingdom and have also outlined the main statistical 
constraints when performing comparisons.14,15 Women should be informed of the outcomes 
associated with both successful and failed reconstructive procedures, along with the 
likelihood of reconstructive failure locally.  They should also be made aware of the likely 
delay before any secondary reconstructive procedure can be undertaken, and the risk that 
they will need to undergo a simple mastectomy, with its associated outcomes, if 
complications arise.  Clinicians should continue to refine their patient and procedure 
selection processes and operative techniques to minimize the risk of flap-related 
complications in the immediate reconstruction context. 
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Table 1. Characteristics of full baseline sample and sub-sample with 18-month quality of 
life data. 
Characteristic Full sample (n = 
17,844) 
Sub-sample (n = 
6,405) 
n % n % 
No reconstruction 12,841 72.0 4,179 65.3 
Immediate reconstruction 3,304 18.5 1,492 23.3 
Delayed reconstruction 1,699 9.5 734 11.5 
Age>65 years 
Missing data 
6,188 
3 
34.3 
0.02 
1,972 
0 
30.8 
0 
Most deprived quintile 
Missing data 
2,614 
906 
14.6 
5.1 
807 
341 
12.6 
5.3 
Non-white ethnicity 
Missing data 
812 
2,131 
4.6 
11.9 
166 
624 
2.6 
9.7 
Smoker 
Missing data 
2,170 
882 
12.2 
4.9 
722 
167 
11.3 
2.6 
Diabetic 
Missing data 
1,067 
327 
6.0 
1.8 
307 
58 
4.8 
0.9 
Obese (BMI 30 or greater) 
Missing data 
4,451 
1,017 
24.9 
5.7 
1,579 
207 
24.7 
3.2 
Grade I (normal) ASA 
Missing data 
8,612 
715 
48.3 
4.0 
3,560 
84 
55.6 
1.3 
Grade 0 (fully active) ECOG 
Missing data 
11,887 
1,047 
66.6 
5.9 
4,845 
211 
75.6 
3.3 
Ductal carcinoma in situ 
Missing data 
2,643 
458 
14.8 
2.6 
1,049 
117 
16.4 
1.8 
High grade DCIS/poorly differentiated tumour 
Missing data 
7,805 
736 
43.7 
4.1 
2,720 
185 
42.5 
2.9 
Overall complication rate 1,822 10.2 629 9.8 
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Table 2. Complication rates in 6,405 patients who reported on their satisfaction with their 
breast appearance 18 months after their surgery. 
Complication type (associated intervention) Reconstruction group 
Mastectomy 
(n = 4,179) 
Immediate 
(n = 1,492) 
Delayed 
(n = 734) 
n % n % n % 
Wound infection (antibiotics) 45 1.1 30 2.0 7 0.9 
Wound infection (debridement) 6 0.1 4 0.3 2 0.3 
Wound dehiscence (re-closure) 6 0.1 21 1.4 3 0.4 
Skin flap necrosis (debridement) 3 0.1 2 0.1 0 0 
Haematoma/seroma (aspiration or drainage) 378 9.0 67 4.5 17 2.3 
All mastectomy site complications 423 10.1 113 7.6 26 3.5 
Impaired flap perfusion (re-exploration/revision) NA NA 13 1.3 22 3.5 
Partial flap necrosis or failure (debridement) NA NA 11 1.1 10 1.6 
Total flap necrosis or failure (removal) NA NA 7 0.7 4 0.6 
All flap complications NA NA 30 3.0 34 5.4 
Displaced implant/expander (re-positioning) NA NA 5 0.6 3 1.1 
Infected implant/expander (intravenous antibiotics) NA NA 9 1.1 1 0.3 
Infected implant/expander (removal) NA NA 14 1.7 0 0 
Ruptured implant/expander (removal) NA NA 2 0.2 0 0 
All implant/expander complications NA NA 27 3.3 4 1.4 
All complications combined 423 10.1 149 10.0 56 7.6 
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Table 3: Breast-area appearance scores for patients with and without complications by type of complication and type of surgery at 18 
months after surgery. 
Surgical group/complication 
type 
No complications Complications Adjusted difference 
(95% CI)* 
P value Covariates in multivariate 
linear regression model n Mean (SD) n Mean (SD) 
Mastectomy-only patients  
Mastectomy site 
complications 
3,756 55.9 (20.3) 423 53.2 (21.4) -2.7 (-4.7 to -0.7) 0.009 Age, smoking status, BMI, 
ECOG, tumour type 
Immediate reconstruction patients  
Mastectomy site 
complications 
1,379 62.1 (20.2) 113 53.9 (18.1) -7.5 (-11.5 to -3.4) <0.001 Deprivation, ASA, tumour type 
Flap-related complications 966 65.4 (19.2) 30 42.2 (20.4) -23.8 (-31.0 to -16.6) <0.001 Ethnicity 
Implant-related complications 786 59.1 (19.6) 27 51.4 (23.4) -8.3 (-17.1 to 0.5) 0.06 Deprivation, ASA 
Delayed reconstruction patients  
Mastectomy site 
complications 
708 68.5 (19.8) 26 67.0 (22.1) -3.2 (-11.1 to 4.7) 0.43 Ethnicity, smoking status, 
ECOG 
Flap-related complications 594 70.7 (19.4) 34 64.0 (21.1) -2.8 (-9.7 to 4.0) 0.42 Ethnicity 
Implant-related complications 280 63.6 (19.6) 4 70.0 (6.2) 5.3 (-13.5 to 24.0) 0.58 Ethnicity, ECOG 
*Negative differences imply better outcomes for patients with no complications 
 
  
23 
 
Table 4: Emotional well-being scores for patients with and without complications by type of complication and type of surgery at 18 months 
after surgery. 
Surgical group/complication 
type 
No complications Complications Adjusted difference 
(95% CI)* 
P value Covariates in multivariate 
linear regression model n Mean (SD) n Mean (SD) 
Mastectomy-only patients  
Mastectomy site 
complications 
3,745 62.8 (21.3) 421 59.5 (22.4) -4.5 (-6.6 to -2.3) 0<0.001 Age, deprivation, smoking 
status, BMI, ASA, tumour type 
Immediate reconstruction patients  
Mastectomy site 
complications 
1,374 69.7 (22.3) 111 64.0 (23.3) -4.9 (-9.4 to -0.3) 0.03 Age, deprivation, smoking 
status, BMI, ASA, ECOG 
Flap-related complications 963 71.9 (21.6) 28 56.7 (23.8) -14.0 (-22.0 to -6.0) 0.001 Age, deprivation, ECOG 
Implant-related complications 783 68.3 (22.1) 27 63.7 (27.5) -7.4 (-17.1 to 2.4) 0.14 Age, deprivation, ASA 
Delayed reconstruction patients  
Mastectomy site 
complications 
703 74.4 (21.9) 26 82.5 (20.6) 6.7 (-2.2 to 15.7) 0.14 Ethnicity, smoking status, BMI, 
ASA, ECOG 
Flap-related complications 592 76.4 (21.2) 34 73.1 (19.9) 1.2 (-6.4 to 8.8) 0.76 Ethnicity, smoking status, ASA, 
ECOG 
Implant-related complications 276 71.7 (22.2) 4 85.5 (18.0) 15.4 (-5.9 to 36.8) 0.16 Smoking status, ECOG 
*Negative differences imply better outcomes for patients with no complications 
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Table 5: Physical well-being scores for patients with and without complications by type of complication and type of surgery at 18 months 
after surgery. 
Surgical group/complication 
type 
No complications Complications Adjusted difference 
(95% CI)* 
P value Covariates in multivariate linear 
regression model n Mean (SD) n Mean (SD) 
Mastectomy-only patients  
Mastectomy site 
complications 
3,742 73.6 (16.7) 421 71.6 (17.7) -2.6 (-4.4 to -0.8) 0.004 Age, deprivation, ethnicity, 
smoking status, BMI, ASA, 
tumour type 
Immediate reconstruction patients  
Mastectomy site 
complications 
1,372 75.1 (15.3) 113 71.2 (17.0) -4.7 (-8.1 to -1.3) 0.007 Age, deprivation, ethnicity, BMI 
Flap-related complications 962 75.1 (15.6) 29 69.2 (13.5) -7.9 (-13.8 to -1.9) 0.009 Age, deprivation, ethnicity 
Implant-related complications 783 75.0 (15.4) 27 76.7 (14.6) -0.8 (-8.3 to 6.6) 0.83 Age, deprivation, ethnicity, ASA 
Delayed reconstruction patients  
Mastectomy site 
complications 
706 76.7 (16.0) 25 81.4 (17.9) 3.5 (-3.2 to 10.2) 0.31 Deprivation, ethnicity, smoking 
status, ECOG 
Flap-related complications 593 77.0 (16.1) 33 80.5 (15.6) 5.9 (-0.1 to 12.0) 0.06 Deprivation, ethnicity, smoking 
status 
Implant-related complications 279 75.5 (16.2) 4 67.0 (7.4) -8.8 (-25.1 to 7.6) 0.29 Deprivation, BMI, ASA 
*Negative differences imply better outcomes for patients with no complications 
 
